Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
How did UNCY's recent EPS compare to expectations?
The most recent EPS for Unicycive Therapeutics Inc is $-0.33, not beating expectations of $-0.56.
How did Unicycive Therapeutics Inc UNCY's revenue perform in the last quarter?
Unicycive Therapeutics Inc revenue for the last quarter is $-0.33
What is the revenue estimate for Unicycive Therapeutics Inc?
According to 8 of Wall street analyst, the revenue estimate of Unicycive Therapeutics Inc range from $0.0 to $0.0
What's the earning quality score for Unicycive Therapeutics Inc?
Unicycive Therapeutics Inc has a earning quality score of B+/55.40547. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Unicycive Therapeutics Inc report earnings?
Unicycive Therapeutics Inc next earnings report is expected in 2026-02-10
What are Unicycive Therapeutics Inc's expected earnings?
Unicycive Therapeutics Inc expected earnings is $0.0, according to wall-street analysts.
Did Unicycive Therapeutics Inc beat earnings expectations?
Unicycive Therapeutics Inc recent earnings of $0.0 does not beat expectations.